IMM 5.36% 29.5¢ immutep limited

Immutep not only leads the way with its LAG-3 research but sets...

  1. 42 Posts.
    lightbulb Created with Sketch. 13

    Immutep not only leads the way with its LAG-3 research but sets the research standard because it was discovered by its Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. This alone has put Immutep as a global leader of immunotherapy drugs for cancer and autoimmune diseases.

    “It’s really what we do. We are a LAG-3 company. We have more programs built around LAG-3 than even anyone, including in the Pharma space,” said Immutep CEO Marc Voigt. “The reality is, there has not been a new, approved or validated checkpoint in the past six years. LAG-3 is our opportunity to be the next big thing in immunization technology.”


    Some pretty confident statements made there
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
29.5¢
Change
0.015(5.36%)
Mkt cap ! $428.5M
Open High Low Value Volume
28.5¢ 30.5¢ 28.0¢ $833.4K 2.824M

Buyers (Bids)

No. Vol. Price($)
8 388130 29.5¢
 

Sellers (Offers)

Price($) Vol. No.
30.0¢ 39940 3
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.